Trends in cancer-targeted antibody–drug conjugates François-Clément BidardOlivier Trédan Review 13 November 2013 Pages: 1 - 8
Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer Luís LeónRoberto García-FiguerasCarmen Sebastiá Review 12 December 2013 Pages: 9 - 24
Caffeic acid phenylethyl ester and MG132, two novel nonconventional chemotherapeutic agents, induce apoptosis of human leukemic cells by disrupting mitochondrial function Victoria CavaliereDaniela L. PapademetrioElida M. C. Álvarez Original Research 22 February 2013 Pages: 25 - 42
EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer Yogesh K. VashistFlorian TrumpJakob R. Izbicki Original Research 02 February 2013 Pages: 43 - 52
Delta-catenin promotes the proliferation and invasion of colorectal cancer cells by binding to E-cadherin in a competitive manner with p120 catenin Hong ZhangShun-Dong DaiChao-Liu Dai Original Research 20 February 2013 Pages: 53 - 61
Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma Laura M. AlwanKenneth GrossmannJeffrey A. Gilreath Original Research 23 April 2013 Pages: 63 - 71
Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor Swati SikariaJosefine Heim-HallMonica Mita Original Research 21 February 2013 Pages: 73 - 79
Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature Amaury DasteMarine Gross-GoupilAlain Ravaud Day-to-Day Practice 03 January 2013 Pages: 81 - 84
Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer Mark Sanford Adis Drug Evaluation 26 March 2014 Pages: 85 - 94